Venture capital poured into innovative startups this week from April 4-10, 2026, with the top 10 rounds totaling over $1.4 billion across semiconductors, aviation, and biotechnology.
SiFive claimed the spotlight by raising a whopping $400 million in a Series G round led by Atreides Management, marking the largest U.S. funding deal of the period.
SiFive's RISC-V Revolution Challenges Chip Dominance
Based in San Mateo, California, SiFive specializes in custom chip blueprints using the open-source RISC-V architecture, empowering companies like Alphabet to bypass proprietary designs from Arm Holdings.
CEO Patrick Little revealed this infusion positions the company for a potential IPO, signaling a maturing trajectory after years of building RISC-V ecosystem momentum amid AI-driven chip demands.
These funds will accelerate custom silicon innovations, impacting everything from data centers to edge computing with greater flexibility and cost savings.
Aviation and Defense Investments Hit New Heights
Hermeus in El Segundo secured $200 million in equity plus $150 million in debt led by Khosla Ventures, catapulting its valuation to $1 billion for hypersonic unmanned military aircraft.
Backed by investors like Founders Fund and RTX Ventures, Hermeus advances autonomous aviation tech critical for national defense, with prototypes paving the way for faster, more efficient operations.
Biotech Breakthroughs Fuel Clinical Advances
Sidewinder Therapeutics raised $137 million in Series B funding from Frazier Life Sciences and Novartis Venture Fund to propel cancer-fighting antibody-drug conjugates into human trials.
Meanwhile, Stipple Bio and Life Biosciences each garnered $100 million and $80 million respectively, targeting precision oncology and cellular rejuvenation for age-related diseases.
Other notables include Aria Networks' $125 million for AI data center optimization and Starfish Space's $111.7 million for satellite servicing spacecraft.
These rounds underscore investor optimism in deep tech's future, from defense autonomy to longevity therapies, promising transformative societal impacts.
Andrew Lee
